Sonia Drozdz1, Michael Schwedas2, Henning Salz2, Susan Foller3, Thomas G Wendt4. 1. Department of Radiation Oncology, University Hospital Jena, Friedrich-Schiller-University Jena, Bachstrasse 18, 07743, Jena, Germany. Sonia.Drozdz@med.uni-jena.de. 2. Department of Radiation Oncology, Section of Medical Physics, University Hospital Jena, Friedrich-Schiller-University Jena, Bachstrasse 18, 07743, Jena, Germany. 3. Department of Urology, University Hospital Jena, Friedrich-Schiller-University Jena, Lessingstrasse 1, 07743, Jena, Germany. 4. Department of Radiation Oncology, University Hospital Jena, Friedrich-Schiller-University Jena, Bachstrasse 18, 07743, Jena, Germany.
Abstract
BACKGROUND: We compared different image-guidance (IG) strategies for prostate cancer with high-precision IG intensity-modulated radiation therapy (IMRT) using TomoTherapy® (Accuray Inc., Madison, WI, USA) and linear accelerator (LINAC)-IMRT and their impact on planning target volume (PTV) margin reduction. Follow-up data showed reduced bladder toxicity in TomoTherapy patients compared to LINAC-IMRT. The purpose of this study was to quantify whether the treatment delivery technique and decreased margins affect reductions in bladder toxicity. PATIENTS AND METHODS: Setup corrections from 30 patients treated with helical TomoTherapy and 30 treated with a LINAC were analyzed. These data were used to simulate three IG protocols based on setup error correction and a limited number of imaging sessions. For all patients, gastrointestinal (GI) and genitourinary (GU) toxicity was documented and correlated with the treatment delivery technique. RESULTS: For fiducial marker (FM)-based RT, a margin reduction of up to 3.1, 3.0, and 4.8 mm in the left-right (LR), superior-inferior (SI), and anterior-posterior (AP) directions, respectively, could be achieved with calculation of a setup correction from the first three fractions and IG every second day. Although the bladder volume was treated with mean doses of 35 Gy in the TomoTherapy group vs. 22 Gy in the LINAC group, we observed less GU toxicity after TomoTherapy. CONCLUSION: Intraprostate FMs allow for small safety margins, help decrease imaging frequency after setup correction, and minimize the dose to bladder and rectum, resulting in lower GU toxicity. In addition, IMRT delivered with TomoTherapy helps to avoid hotspots in the bladder neck, a critical anatomic structure associated with post-RT urinary toxicity.
BACKGROUND: We compared different image-guidance (IG) strategies for prostate cancer with high-precision IG intensity-modulated radiation therapy (IMRT) using TomoTherapy® (Accuray Inc., Madison, WI, USA) and linear accelerator (LINAC)-IMRT and their impact on planning target volume (PTV) margin reduction. Follow-up data showed reduced bladder toxicity in TomoTherapy patients compared to LINAC-IMRT. The purpose of this study was to quantify whether the treatment delivery technique and decreased margins affect reductions in bladder toxicity. PATIENTS AND METHODS: Setup corrections from 30 patients treated with helical TomoTherapy and 30 treated with a LINAC were analyzed. These data were used to simulate three IG protocols based on setup error correction and a limited number of imaging sessions. For all patients, gastrointestinal (GI) and genitourinary (GU) toxicity was documented and correlated with the treatment delivery technique. RESULTS: For fiducial marker (FM)-based RT, a margin reduction of up to 3.1, 3.0, and 4.8 mm in the left-right (LR), superior-inferior (SI), and anterior-posterior (AP) directions, respectively, could be achieved with calculation of a setup correction from the first three fractions and IG every second day. Although the bladder volume was treated with mean doses of 35 Gy in the TomoTherapy group vs. 22 Gy in the LINAC group, we observed less GU toxicity after TomoTherapy. CONCLUSION: Intraprostate FMs allow for small safety margins, help decrease imaging frequency after setup correction, and minimize the dose to bladder and rectum, resulting in lower GU toxicity. In addition, IMRT delivered with TomoTherapy helps to avoid hotspots in the bladder neck, a critical anatomic structure associated with post-RT urinary toxicity.
Entities:
Keywords:
Adverse effects; Fiducial markers; Margins; Organs at risk; Tomotherapy
Authors: S Hynds; C K McGarry; D M Mitchell; S Early; L Shum; D P Stewart; J A Harney; C R Cardwell; J M O'Sullivan Journal: Br J Radiol Date: 2010-12-15 Impact factor: 3.039
Authors: James A Tanyi; Tongming He; Paige A Summers; Ruth G Mburu; Catherine M Kato; Stephen M Rhodes; Arthur Y Hung; Martin Fuss Journal: Int J Radiat Oncol Biol Phys Date: 2010-05-14 Impact factor: 7.038
Authors: Michel J Ghilezan; David A Jaffray; Jeffrey H Siewerdsen; Marcel Van Herk; Anil Shetty; Michael B Sharpe; Syed Zafar Jafri; Frank A Vicini; Richard C Matter; Donald S Brabbins; Alvaro A Martinez Journal: Int J Radiat Oncol Biol Phys Date: 2005-06-01 Impact factor: 7.038
Authors: Katja M Langen; Yashan Zhang; Rhonda D Andrews; Monica E Hurley; Sanford L Meeks; Darrell O Poole; Twyla R Willoughby; Patrick A Kupelian Journal: Int J Radiat Oncol Biol Phys Date: 2005-08-01 Impact factor: 7.038
Authors: Eugene Huang; Lei Dong; Anurag Chandra; Deborah A Kuban; Isaac I Rosen; Anissa Evans; Alan Pollack Journal: Int J Radiat Oncol Biol Phys Date: 2002-06-01 Impact factor: 7.038
Authors: Homan Dehnad; Aart J Nederveen; Uulke A van der Heide; R Jeroen A van Moorselaar; Pieter Hofman; Jan J W Lagendijk Journal: Radiother Oncol Date: 2003-06 Impact factor: 6.280
Authors: Lara Hathout; Michael R Folkert; Marisa A Kollmeier; Yoshiya Yamada; Gil'ad N Cohen; Michael J Zelefsky Journal: Int J Radiat Oncol Biol Phys Date: 2014-10-01 Impact factor: 7.038
Authors: Una M O'Doherty; Helen A McNair; Andrew R Norman; Elizabeth Miles; Simon Hooper; Mark Davies; Naomi Lincoln; Jan Balyckyi; Peter Childs; David P Dearnaley; Robert A Huddart Journal: Radiother Oncol Date: 2006-06-16 Impact factor: 6.280